Tenax Therapeutics has appointed a new chief financial officer. The company's stock has been initiated with an outperform rating by Evercore ISI, but some analysts view it as a speculative or binary bet with potential downside. The stock is also being considered as a cheap penny stock option, with some outlets suggesting it as a buy, while others express caution.